SALT LAKE CITY, January 6, 2026 – Utah has launched the nation’s first pilot program allowing an artificial intelligence system to independently renew prescriptions for chronic conditions, partnering with health-tech startup Doctronic under the state’s regulatory sandbox.
The 12-month initiative, approved by the Utah Department of Commerce’s Office of Artificial Intelligence Policy, permits Doctronic’s AI platform to handle refills for 190 routine medications, excluding controlled substances, ADHD treatments, pain management drugs, and injectables.
Patients access the service online, where the AI verifies eligibility, reviews history, and conducts a clinical interview mirroring physician questions before approving and sending renewals to pharmacies.
Doctronic charges $4 per renewal during the pilot, with potential for insurance coverage or scaled pricing. Co-founder Dr. Adam Oskowitz said company data showed the AI matching human physician plans in 99.2% of 500 reviewed cases.
Safeguards include automatic referral to doctors for uncertainty, initial human review of the first 250 prescriptions per drug class, and interaction checks.
Margaret Busse, commerce department executive director, described the program as advancing access: “Provide a pathway to innovation for entrepreneurs who are using AI in creative ways.” It addresses medication non-adherence, linked to preventable harm and costs over $100 billion nationally annually.
The American Medical Association voiced caution. Dr. John Whyte warned: “While AI has limitless opportunity to transform medicine for the better, without physician input it also poses serious risks to patients and physicians alike.” The Utah Medical Association echoed concerns over missed nuances in patient care.
The pilot will collect data on safety, adherence, and outcomes for public reporting. Other states, including Arizona and Texas, operate similar sandboxes for AI testing.
Utah’s move reflects growing experimentation with AI in healthcare administration, balancing efficiency gains against clinical oversight needs.
